Arcus Biosciences (NYSE:RCUS) Insider Richard Markus Sells 4,494 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) insider Richard Markus sold 4,494 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total value of $99,587.04. Following the completion of the sale, the insider owned 65,647 shares in the company, valued at approximately $1,454,737.52. This represents a 6.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Richard Markus also recently made the following trade(s):

• On Tuesday, December 16th, Richard Markus sold 5,052 shares of Arcus Biosciences stock. The stock was sold at an average price of $21.88, for a total transaction of $110,537.76.

Arcus Biosciences Price Performance

NYSE RCUS traded down $0.26 during trading hours on Thursday, hitting $22.02. 1,175,874 shares of the company’s stock traded hands, compared to its average volume of 1,200,446. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $26.40. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. The firm’s 50-day moving average is $20.82 and its 200-day moving average is $13.98. The company has a market capitalization of $2.38 billion, a PE ratio of -6.40 and a beta of 0.75.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million during the quarter, compared to analysts’ expectations of $19.89 million. During the same period last year, the business earned ($1.00) earnings per share. The business’s revenue for the quarter was down 45.8% on a year-over-year basis. Equities analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its stake in Arcus Biosciences by 106.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after acquiring an additional 470,755 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Arcus Biosciences by 14.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock valued at $12,995,000 after purchasing an additional 207,097 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Arcus Biosciences by 14.8% in the first quarter. Rhumbline Advisers now owns 182,909 shares of the company’s stock worth $1,436,000 after buying an additional 23,645 shares during the last quarter. Tema Etfs LLC lifted its holdings in Arcus Biosciences by 291.2% in the 2nd quarter. Tema Etfs LLC now owns 59,662 shares of the company’s stock worth $486,000 after purchasing an additional 44,411 shares during the last quarter. Finally, Woodline Partners LP raised its holdings in Arcus Biosciences by 45.5% in the 1st quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock worth $40,249,000 after acquiring an additional 1,603,367 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on RCUS shares. Truist Financial set a $30.00 target price on shares of Arcus Biosciences in a research note on Friday, December 12th. UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research note on Monday. Citigroup restated a “buy” rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Wedbush set a $35.00 target price on shares of Arcus Biosciences and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Finally, Bank of America raised their target price on shares of Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.89.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.